Harmonizing outcomes with revascularization and stents horizons trial
Download
1 / 3

Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial - PowerPoint PPT Presentation


  • 249 Views
  • Uploaded on
  • Presentation posted in: General

HORIZONS Trial. Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial. HORIZONS Trial: Study Design. 3400 patients undergoing primary PCI first randomized 1:1 to anti-thrombotic therapy then ~88% (3000) patients randomized 3:1 to target vessel stenting

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha

Download Presentationdownload

Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Harmonizing outcomes with revascularization and stents horizons trial l.jpg

HORIZONS Trial

Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial


Horizons trial study design l.jpg

HORIZONS Trial: Study Design

3400 patients undergoing primary PCI first randomized 1:1 to anti-thrombotic therapy then ~88% (3000) patients randomized 3:1 to target vessel stenting

1, 6, and 12 month follow-up for all patients undergoing primary randomization, angiography at 13 months for 1500 stent randomized patients only, yearly follow-up for 5 years for all patients.

Antithrombotic Therapy

Randomized 1:1

Bivalirudin + Bail-Out IIb/IIIa Inhibitor

n=1700

UFH + IIb/IIIa Inhibitor

n=1700

Target Vessel Stenting to DES vs BMS Randomized 3:1

  • Hypothesis 1: Bivalirudin compared to UFH + routine IIb/IIIa will reduce the composite rate of death, reinfarction, TVR, stroke, and major bleeding at 30 days

Presented at TCT 2005


Slide3 l.jpg

HORIZONS Trial: Study Design

3400 patients undergoing primary PCI first randomized 1:1 to anti-thrombotic therapy then ~88% (3000) patients randomized 3:1 to target vessel stenting

1, 6, and 12 month follow-up for all patients undergoing primary randomization, angiography at 13 months for 1500 stent randomized patients only, yearly follow-up for 5 years for all patients.

Antithrombotic Therapy

Randomized 1:1

Target Vessel Stenting

Randomized 3:1

TAXUS stent

n=2250

Bare metal Express stent

n=750

  • Hypothesis 2: Use of polymer-based slow-release paclitaxel-eluting TAXUS stent will safely reduce the 1 year rate of ischemia-driven TLR

Presented at TCT 2005


ad
  • Login